MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Arix Bioscience's pipeline bolstered with launch of three new clinical trials

StockMarketWire.com

Arix Bioscience said Friday its three group businesses had launched three new clinical trials boosting the company's pipeline. Iterum Therapeutics initiated a phase 3 clinical trial of its urinary tract Infections treatment -- the first of three planned phase 3 pivotal trials. Top-line results are expected in second half of 2019 and NDA submission anticipated by the end of 2019, the company said. Harpoon Therapeutics treated the first patient with its prostate cancer treatment (HPN424) in its phase 1 clinical study of metastatic castration-resistant prostate cancer patients. Verona Pharma had initiated a phase 2 clinical trial to evaluate its lung treatment (Nebulized RPL554) as an add on to Dual Bronchodilator Therapy for COPD maintenance treatment. Top line data is expected in the first quarter 2019. 'We are pleased to note the initiation of new trials by Iterum Therapeutics, Harpoon Therapeutics and Verona Pharma,' said Joe Anderson, CEO of Arix Bioscience.





Story provided by StockMarketWire.com